PaediatricNCT07841340
The Efficacy and Safety of Adjunctive Alpha-blocker Therapy Before Flexible Ureteroscopy in the Management of Upper Ureteric Stones in Pediatrics Group
A study testing Tamsulosin in people with Paediatric and Flexible Ureteroscopy, run by Ain Shams University at 1 site in Egypt.
Trial summary
A unique aspect of pediatric URS is the smaller ureteral diameter, which often results in failure to access the ureter during an initial URS attempt. Ureteral orifice navigation is often limited at the level of the ureteral orifice or intramural ureter. Read more about this study
- Who is it for?
- Ages 5 to 18 years
- Conditions the study is for
- Paediatric, Flexible Ureteroscopy
- What is being tested?
- Tamsulosin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteEgypt
- Study dates
- 4 Sep 2022to 1 Sep 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Age between 5:18 years
- Children with upper ureteric stones
Who cannot join
- Children with active urosepsis.
- Children with ureteral stricture
- Children with past history of ureteric endoscopy or stent application.
- Children with bilateral ureteral stones.
- Children with congenital anomalies e.g. solitary kidney, duplex system, ureterocele.
- Those with hypersensitivity to α-blockers.
- Known hypotensive or bradycardic patients.
Trial locations and contacts
1 site in 1 country.
About this study
A unique aspect of pediatric URS is the smaller ureteral diameter, which often results in failure to access the ureter during an initial URS attempt.
Ureteral orifice navigation is often limited at the level of the ureteral orifice or intramural ureter. α1 adrenergic receptors are densely located at this level, and α-antagonists can reduce the tension of the intramural segment The purpose of this study was to evaluate if preoperative treatment with tamsulosin is associated with an increased rate of successful first-time ureteral orifice navigation in a school-age pediatric population, defined as patients 5-18 years old.
Read the detailed description
The incidence of pediatric urolithiasis has risen dramatically over the past few decades, with a reported rate of 4% per year .There is controversy regarding the practice of routine prestenting and balloon dilation to gain ureteral access in children. The AUA guidelines recommend against the routine use of prestenting. Balloon dilation of the ureteral orifice carries the risk of ureteral perforation and ureteral stricture, due to tissue ischemia .There are three subtypes of alpha- 1 adrenoceptors (ARs) in the ureteric wall: alpha-1A, alpha-1B and alpha-1D. In the proximal ureter, the distribution of ARs was alpha-1D ≥alpha-1B >alpha-1A. In the distal and middle ureters, the distribution of ARs was alpha-1D > alpha-1A > alpha-1B . Tamsulosin acts on α1A and α1D receptors causing the relaxation of the ureteric wall, which consequently increases the urine bolus and intra-ureteral pressure above the stone and lowers intra-ureteral pressure below the stone by decreasing peristalsis in association with the decrease in basal and micturition pressure, even at the bladder neck; thus, it increases the chance of stone expulsion .The management of ureteric stones consists of observation, medical expulsive therapy (MET), shockwave lithotripsy (SWL), ureteroscopy, percutaneous nephrolithotomy or open and laparoscopic stone surgery, depending on the clinical situation .The presumed mechanism of action of alphablockers is the inhibition of smooth muscle contraction in the ureter, causing relaxation of the ureter smooth muscle and reducing the strength and frequency of peristalsis .Flexible ureteroscopy (FURS) has been applied in recent years to the treatment of urinary stones. FURS presents overt advantages over other techniques, including improved resolution and increased optical field, high stone-free rate, reduced risk of bleeding, limited surgical injury, good repeatability, and speedy recovery; in addition, further miniaturization is possible. In children and infants, who have a relatively high stone recurrence rate, FURS could be performed repeatedly. FURS and holmium laser lithotripsy in treating infants and children has been previously assessed in the literature; however, most reports were limited in sample size.
Aim of the study:To evaluate efficacy adjunctive alpha-blocker therapy before Flexible ureteroscopy in the management of Upper ureteric stones in children as regard facilitating ureteric orifice navigation, Ureteral Dilatation, intraoperative and postoperative Complication, patient satisfaction and stone free rate.
PATIENTS AND METHODS This was a prospective randomized control study that was conducted at tertiary care hospital between September 2022 till September 2024. The study was approved by the Research Ethics Committee (REC) of Ain Shams University Faculty of Medicine. A detailed written informed consent was secured from patients' parents included in the study before enrollment after explaining the benefits and risks of the medication and procedure.
Eligibility criteria We included all children aged between 5 and 18 years with upper ureteric stones. Patients excluded from the analysis were children with active urosepsis, ureteral stricture, bilateral ureteral stones, children with already stented ureter, Children with congenital anomalies e.g. solitary kidney, duplex system, ureterocele, Those with hypersensitivity to α-blockers and Known hypotensive or bradycardic patients.
Participants and group allocation A total of 80 patients were included and randomly allocated into two groups depending on simple one to one randomization utilizing a sealed envelope prepared by an independent third party to ensure unbiased distribution. Outcome assessors, and statisticians were blinded to the treatment to minimize bias.. Group A: 40 Children received Tamsulosin 0.4 mg capsule for 5 days prior to Flexible uretroscopy. Group B: 40 Children didn't receive Tamsulosin 0.4 mg capsule prior to Flexible uretroscopy.
Pre-treatment assessment and baseline investigations All patients underwent a thorough clinical history and physical examination. Detailed medical history and surgical history including any surgery of the urinary tract, DJ application and ESWL. Laboratory work up including complete blood count (CBC), kidney functions test, liver functions test, hepatitis markers, coagulation profile, completer urine analysis and urine culture with sensitivity. All patients were subjected to imaging studies including pelvi-abdominal ultrasound, plain X-ray of urinary tract and CTUT All patients performed KUB in the morning day of the operation.
Alpha Blocker (Tamsulosin) 0.4 mg/dl was given once daily before sleep for 5 days to Group A only. Patients received preoperative prophylactic antibiotic. All cases had been performed by the same standard approach for Flexible Uretroscopy
Flexible uretroscopy:
The procedures were performed under general anesthesia in frog leg or lithotomy position in all patients. we start with cystoscopy followed by guide-wire insertion up to the renal pelvis and retrograde pyelography. Ureteral dilation was performed by teflon dilators up to 8 fr Then, we attempt to advocate the 7.5 fr flexible ureteroscope over the guide wire under direct vision up to the stone level. In all cases, Stone disintegration was done using Holmium Laser System and 200-micron laser fiber in dusting mode. A double-J stent was placed at the end of the procedure. Urethral catheter was left at end of procedure. DJ stents was removed 2 - 4 weeks after the operation. If navigation of the ureteral orifice is unsuccessful, then a ureteral JJ stent is placed for 10-14 days before attempting a second URS.
Postoperative:
Postoperatively, all patient had CBC done a few hours after the procedure, monitored for vital signs and urine color. All patients were assessed for residual stone presence 3 weeks after procedure by CTUT. The intraoperative and postoperative complications (e.g. fever, hematuria…), stone-free rate, and hospital stay were were reported according to the modified Clavien grading system. The primary endpoint was defined as being able to engage the flexible ureteroscope in the ureteral orifice to be able to perform the intended procedure. The second endpoint are safety of tamsulosin, intraoperative and postoperative Complication.
Statistical Analysis Data were collected, revised, coded and entered to the Statistical Package for Social Science (IBM SPSS) version 20. The qualitative data were presented as number and percentages while quantitative data were presented as mean, standard deviations and ranges when their distribution found parametric.
The comparison between two groups with qualitative data were done by using Chi-square test and/or Fisher exact test was used instead of Chi-square test when the expected count in any cell was found less than 5. The comparison between two independent groups with quantitative data and parametric distribution was done by using Independent t-test.
The confidence interval was set to 95% and the margin of error accepted was set to 5%. So, the p-value was considered significant as the following: P> 0.05 = non significant (NS), P < 0.05 = significant (S) and P < 0.001 = highly significant (HS).
- Conditions
- Paediatric, Flexible Ureteroscopy
- Being tested
- Tamsulosin
- Keywords
- paediatric, alpha blocker, flexible ureteroscopy, tamsulosin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TamsulosinDrug
Children will receive Tamsulosin 0.4 mg ( alpha blocker) capsule for 5 days prior to Flexible uretroscopy
| Study group | Role | What they receive |
|---|---|---|
| interventional | Experimental | Children with ureteric stones with age between 5:18 years will receive Tamsulosin 0.4 mg capsule for 5 days prior to Flexible uretroscopy Receives: Drug: Tamsulosin |
| control | No intervention | Children with ureteric stones with age between 5:18 years will not receive Tamsulosin 0.4 mg capsule prior to Flexible uretroscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Successful Flexible Ureteroscope Negotiation Through the Ureteral Orifice in tamsulosin group versus non tamsulosin group
Successful negotiation is defined as advancement of the flexible ureteroscope through the ureteral orifice and into the ureter sufficiently to allow performance of the intended ureteroscopic procedure. The outcome will be recorded as the number and percentage of participants with successful negotiation in each treatment group
Measured: Intraoperative, during flexible ureteroscopy
Secondary outcomes (2)
Number of Participants with Intraoperative or Postoperative Complications Following Flexible Ureteroscopy
Intraoperative and postoperative complications will be recorded for each participant. Complications will include ureteral injury, bleeding/hematuria, postoperative fever, urinary tract infection, ureteral perforation, postoperative pain requiring additional treatment, and other clinically relevant complications. Complications will be classified according to the modified Clavien-Dindo classification system. The outcome will be reported as the number and percentage of participants experiencing at least one complication in each treatment group.
Measured: From the beginning of flexible ureteroscopy until 1 month postoperatively
Number of Participants with Tamsulosin-Related Adverse Events Following Preoperative Tamsulosin Administration.
Adverse events potentially related to tamsulosin will be assessed during the preoperative treatment period and perioperative period. Events assessed will include dizziness, headache, hypotension, orthostatic hypotension, syncope, gastrointestinal symptoms, and other clinically relevant adverse events. The outcome will be reported as the number and percentage of participants experiencing at least one treatment-related adverse event in each treatment group
Measured: From initiation of tamsulosin until the day of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study start4 Sep 2022
- Primary completion4 Apr 2023
- Study completion1 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PaediatricStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- Children with ureteric stones ranging from 5-10 mm Age between 5:18 years
- Masking
- None (open label)
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07841340
- Sponsor's protocol ID
- FMASU MS569/2022
- Status last verified
- Sep 2026
- First submitted
- 9 Sep 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Efficacy and Safety of Adjunctive Alpha-blocker Therapy Before Flexible Ureteroscopy in the Management of Upper Ureteric Stones in Pediatrics Group
- ClinicalTrials.gov ID
- NCT07841340
- Acronym / sponsor ID
- FMASU MS569/2022
- Conditions
- Paediatric, Flexible Ureteroscopy
- Keywords
- paediatric, alpha blocker, flexible ureteroscopy, tamsulosin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 4 Sep 2022 (actual)
- Primary completion
- 4 Apr 2023 (actual)
- Study completion
- 1 Sep 2024 (actual)
- First posted
- 25 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A unique aspect of pediatric URS is the smaller ureteral diameter, which often results in failure to access the ureter during an initial URS attempt.
Ureteral orifice navigation is often limited at the level of the ureteral orifice or intramural ureter. α1 adrenergic receptors are densely located at this level, and α-antagonists can reduce the tension of the intramural segment The purpose of this study was to evaluate if preoperative treatment with tamsulosin is associated with an increased rate of successful first-time ureteral orifice navigation in a school-age pediatric population, defined as patients 5-18 years old.
Detailed description
The incidence of pediatric urolithiasis has risen dramatically over the past few decades, with a reported rate of 4% per year .There is controversy regarding the practice of routine prestenting and balloon dilation to gain ureteral access in children. The AUA guidelines recommend against the routine use of prestenting. Balloon dilation of the ureteral orifice carries the risk of ureteral perforation and ureteral stricture, due to tissue ischemia .There are three subtypes of alpha- 1 adrenoceptors (ARs) in the ureteric wall: alpha-1A, alpha-1B and alpha-1D. In the proximal ureter, the distribution of ARs was alpha-1D ≥alpha-1B >alpha-1A. In the distal and middle ureters, the distribution of ARs was alpha-1D > alpha-1A > alpha-1B . Tamsulosin acts on α1A and α1D receptors causing the relaxation of the ureteric wall, which consequently increases the urine bolus and intra-ureteral pressure above the stone and lowers intra-ureteral pressure below the stone by decreasing peristalsis in association with the decrease in basal and micturition pressure, even at the bladder neck; thus, it increases the chance of stone expulsion .The management of ureteric stones consists of observation, medical expulsive therapy (MET), shockwave lithotripsy (SWL), ureteroscopy, percutaneous nephrolithotomy or open and laparoscopic stone surgery, depending on the clinical situation .The presumed mechanism of action of alphablockers is the inhibition of smooth muscle contraction in the ureter, causing relaxation of the ureter smooth muscle and reducing the strength and frequency of peristalsis .Flexible ureteroscopy (FURS) has been applied in recent years to the treatment of urinary stones. FURS presents overt advantages over other techniques, including improved resolution and increased optical field, high stone-free rate, reduced risk of bleeding, limited surgical injury, good repeatability, and speedy recovery; in addition, further miniaturization is possible. In children and infants, who have a relatively high stone recurrence rate, FURS could be performed repeatedly. FURS and holmium laser lithotripsy in treating infants and children has been previously assessed in the literature; however, most reports were limited in sample size.
Aim of the study:To evaluate efficacy adjunctive alpha-blocker therapy before Flexible ureteroscopy in the management of Upper ureteric stones in children as regard facilitating ureteric orifice navigation, Ureteral Dilatation, intraoperative and postoperative Complication, patient satisfaction and stone free rate.
PATIENTS AND METHODS This was a prospective randomized control study that was conducted at tertiary care hospital between September 2022 till September 2024. The study was approved by the Research Ethics Committee (REC) of Ain Shams University Faculty of Medicine. A detailed written informed consent was secured from patients' parents included in the study before enrollment after explaining the benefits and risks of the medication and procedure.
Eligibility criteria We included all children aged between 5 and 18 years with upper ureteric stones. Patients excluded from the analysis were children with active urosepsis, ureteral stricture, bilateral ureteral stones, children with already stented ureter, Children with congenital anomalies e.g. solitary kidney, duplex system, ureterocele, Those with hypersensitivity to α-blockers and Known hypotensive or bradycardic patients.
Participants and group allocation A total of 80 patients were included and randomly allocated into two groups depending on simple one to one randomization utilizing a sealed envelope prepared by an independent third party to ensure unbiased distribution. Outcome assessors, and statisticians were blinded to the treatment to minimize bias.. Group A: 40 Children received Tamsulosin 0.4 mg capsule for 5 days prior to Flexible uretroscopy. Group B: 40 Children didn't receive Tamsulosin 0.4 mg capsule prior to Flexible uretroscopy.
Pre-treatment assessment and baseline investigations All patients underwent a thorough clinical history and physical examination. Detailed medical history and surgical history including any surgery of the urinary tract, DJ application and ESWL. Laboratory work up including complete blood count (CBC), kidney functions test, liver functions test, hepatitis markers, coagulation profile, completer urine analysis and urine culture with sensitivity. All patients were subjected to imaging studies including pelvi-abdominal ultrasound, plain X-ray of urinary tract and CTUT All patients performed KUB in the morning day of the operation.
Alpha Blocker (Tamsulosin) 0.4 mg/dl was given once daily before sleep for 5 days to Group A only. Patients received preoperative prophylactic antibiotic. All cases had been performed by the same standard approach for Flexible Uretroscopy
Flexible uretroscopy:
The procedures were performed under general anesthesia in frog leg or lithotomy position in all patients. we start with cystoscopy followed by guide-wire insertion up to the renal pelvis and retrograde pyelography. Ureteral dilation was performed by teflon dilators up to 8 fr Then, we attempt to advocate the 7.5 fr flexible ureteroscope over the guide wire under direct vision up to the stone level. In all cases, Stone disintegration was done using Holmium Laser System and 200-micron laser fiber in dusting mode. A double-J stent was placed at the end of the procedure. Urethral catheter was left at end of procedure. DJ stents was removed 2 - 4 weeks after the operation. If navigation of the ureteral orifice is unsuccessful, then a ureteral JJ stent is placed for 10-14 days before attempting a second URS.
Postoperative:
Postoperatively, all patient had CBC done a few hours after the procedure, monitored for vital signs and urine color. All patients were assessed for residual stone presence 3 weeks after procedure by CTUT. The intraoperative and postoperative complications (e.g. fever, hematuria…), stone-free rate, and hospital stay were were reported according to the modified Clavien grading system. The primary endpoint was defined as being able to engage the flexible ureteroscope in the ureteral orifice to be able to perform the intended procedure. The second endpoint are safety of tamsulosin, intraoperative and postoperative Complication.
Statistical Analysis Data were collected, revised, coded and entered to the Statistical Package for Social Science (IBM SPSS) version 20. The qualitative data were presented as number and percentages while quantitative data were presented as mean, standard deviations and ranges when their distribution found parametric.
The comparison between two groups with qualitative data were done by using Chi-square test and/or Fisher exact test was used instead of Chi-square test when the expected count in any cell was found less than 5. The comparison between two independent groups with quantitative data and parametric distribution was done by using Independent t-test.
The confidence interval was set to 95% and the margin of error accepted was set to 5%. So, the p-value was considered significant as the following: P> 0.05 = non significant (NS), P < 0.05 = significant (S) and P < 0.001 = highly significant (HS).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Children with ureteric stones ranging from 5-10 mm Age between 5:18 years
| Arm | Type | Receives |
|---|---|---|
| interventional | Experimental | Drug: TamsulosinChildren with ureteric stones with age between 5:18 years will receive Tamsulosin 0.4 mg capsule for 5 days prior to Flexible uretroscopy |
| control | No intervention | –Children with ureteric stones with age between 5:18 years will not receive Tamsulosin 0.4 mg capsule prior to Flexible uretroscopy |
Who may qualify
- Ages
- 5 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (2 listed)
- Age between 5:18 years
- Children with upper ureteric stones
Key exclusion criteria (7 listed)
- Children with active urosepsis.
- Children with ureteral stricture
- Children with past history of ureteric endoscopy or stent application.
- Children with bilateral ureteral stones.
- Children with congenital anomalies e.g. solitary kidney, duplex system, ureterocele.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TamsulosinChildren will receive Tamsulosin 0.4 mg ( alpha blocker) capsule for 5 days prior to Flexible uretroscopy | Drug | interventional |
Primary outcome
Number of Participants with Successful Flexible Ureteroscope Negotiation Through the Ureteral Orifice in tamsulosin group versus non tamsulosin group
Time frame: Intraoperative, during flexible ureteroscopy
Successful negotiation is defined as advancement of the flexible ureteroscope through the ureteral orifice and into the ureter sufficiently to allow performance of the intended ureteroscopic procedure. The outcome will be recorded as the number and percentage of participants with successful negotiation in each treatment group
2 secondary outcomes
Number of Participants with Intraoperative or Postoperative Complications Following Flexible Ureteroscopy
Time frame: From the beginning of flexible ureteroscopy until 1 month postoperatively
Number of Participants with Tamsulosin-Related Adverse Events Following Preoperative Tamsulosin Administration.
Time frame: From initiation of tamsulosin until the day of surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
Related trials for Paediatric
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
RecruitingObservational study
Psychological Benefits of a Normalized Camping Experience for Children With Cancer
Pediatric Cancer
Not yet recruitingObservational study
AI-assisted Tracheal Intubation in Children
Intubation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tamsulosin in people with Paediatric and Flexible Ureteroscopy, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Successful Flexible Ureteroscope Negotiation Through the Ureteral Orifice in tamsulosin group versus non tamsulosin group (time frame: Intraoperative, during flexible ureteroscopy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.